A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma
- Bradley McGregor
- , Daniel M. Geynisman
- , Mauricio Burotto
- , Cristina Suárez
- , Maria T. Bourlon
- , Pedro C. Barata
- , Shuchi Gulati
- , Stephen Huo
- , Flavia Ejzykowicz
- , Steven I. Blum
- , Viviana Del Tejo
- , Melissa Hamilton
- , Jessica R. May
- , Ella X. Du
- , Aozhou Wu
- , Pavol Kral
- , Cristina Ivanescu
- , Andi Chin
- , Keith A. Betts
- , Chung Han Lee
- Dana-Farber Cancer Institute
- Vall d'Hebron Institute of Oncology
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Tulane University
- University of Cincinnati
- Bristol-Myers Squibb
- Analysis Group, Inc.
- Patient Centered Solutions
- Memorial Sloan-Kettering Cancer Center
- Northwestern University
- University of Bari
Research output: Contribution to journal › Article › peer-review
5
Scopus
citations